RXi licences ovarian cancer vax

Worcester, MA-based RXi Pharmaceuticals has licensed an ovarian cancer vaccine from The University of Texas MD Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine. The vaccine, which is designed to prevent the recurrence of endometrial adenocarcinomas, as well as ovarian and other gynecological cancers, targets folate binding protein-E39. FBP is overexpressed in ovarian and aggressive endometrial cancers, as well as breast, lung, colorectal and renal cell carcinomas. Phase I trials will begin later this year. Release

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.